How long should Xarelto (rivaroxaban) be held prior to a colonoscopy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Rivaroxaban (Xarelto) Discontinuation Before Colonoscopy

For patients with normal renal function (CrCl ≥50 mL/min), rivaroxaban (Xarelto) should be discontinued 1-3 days before colonoscopy, with 2 days being optimal for most patients. 1

Factors Affecting Discontinuation Timing

The timing of rivaroxaban discontinuation depends on two key factors:

  1. Renal Function:

    • Normal renal function (CrCl ≥50 mL/min): 1-3 days before procedure
    • Moderate renal impairment (CrCl 30-50 mL/min): 2-4 days before procedure
    • Severe renal impairment (CrCl 15-29.9 mL/min): 3-5 days before procedure 1
  2. Procedure Bleeding Risk:

    • Low-risk procedures (diagnostic colonoscopy with biopsies): 1-2 days
    • High-risk procedures (colonoscopy with polypectomy, EMR, ESD): 2-3 days 1

Practical Approach to Rivaroxaban Management

Pre-Procedure:

  • Assess the patient's renal function using CrCl or eGFR
  • Determine procedure bleeding risk (diagnostic vs. therapeutic colonoscopy)
  • Evaluate patient's thrombotic risk (mechanical heart valves, recent VTE, etc.)
  • For standard colonoscopy with potential polypectomy in patients with normal renal function, stop rivaroxaban 2 days before the procedure 1
  • No bridging therapy with heparin is typically needed when interrupting rivaroxaban 1

Special Considerations:

  • For patients at extremely high thrombotic risk (recent PE/DVT), consider bridging with enoxaparin starting 24 hours after the last rivaroxaban dose 1
  • If bridging is used, administer the last dose of enoxaparin at least 24 hours before the procedure 1

Post-Procedure:

  • Resume rivaroxaban 24 hours after low bleeding risk procedures
  • Resume 48-72 hours after high bleeding risk procedures (e.g., large polypectomy) 1
  • For high thrombotic risk patients after high-risk procedures, consider starting with a reduced dose (10 mg once daily) for the first 1-2 days 1

Common Pitfalls and Caveats

  • Avoid same-day discontinuation: Unlike some antiplatelet agents, rivaroxaban requires at least 24 hours of discontinuation before procedures due to its bleeding risk 2
  • Don't forget to check renal function: Patients with impaired renal function need longer discontinuation periods 1
  • Consider procedure complexity: If multiple or large polyps are anticipated, longer discontinuation may be prudent
  • Resumption timing matters: Restarting too early increases bleeding risk, while delaying too long increases thrombotic risk 1
  • No laboratory monitoring needed: Unlike warfarin, routine laboratory monitoring of rivaroxaban concentration is not required when following recommended interruption periods 1

Comparison to Other Anticoagulants

For context, warfarin management differs significantly:

  • Warfarin typically requires 5 days of discontinuation before high-risk procedures 3
  • INR should be checked prior to the procedure to ensure it's <1.5 3
  • For high thrombotic risk patients on warfarin, bridging with LMWH is recommended 3

By following these guidelines for rivaroxaban discontinuation before colonoscopy, you can minimize both bleeding and thrombotic risks while ensuring an effective procedure.

References

Guideline

Peri-Procedural Management of Anticoagulants for Colonoscopy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.